XSTO
IMMNOV
Market cap2mUSD
Oct 09, Last price
0.08SEK
1D
12.06%
1Q
-60.02%
Jan 2017
-99.91%
IPO
-99.72%
Name
Immunovia AB (publ)
Chart & performance
P/E
—
P/S
39.50
EPS
—
Div yield, %
—
Shrs. gr., 5y
71.82%
Rev. gr., 5y
13.60%
Revenues
685k
-26.42%
Net income
-146m
L+90.64%
CFO
-78m
L-18.97%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Immunovia AB engages in the development of methods for diagnosing complex forms of cancer and autoimmune diseases. Its technology platform, IMMray, focuses on the early diagnosis of cancer, predicts disease progression, and monitors therapeutic responsiveness of cancers. The company was founded by Karl Arne Krister Borrebaeck on May 24, 2007 and is headquartered in Lund, Sweden.
Key people
Lotta Blomgren
Operations Director · since 2016
Michael Pettigrew
Senior Vice President - Sales NA · since 2020
Peter Schultz-Knappe
Chief Technology Officer · since 2019
Rolf Ehrnstrom
Chief Scientific Officer · since 2013
Julie Silber
Director of Investor Relations · since 2019
Mimmi Ekberg
Director · since 2018
Headquarters & legal address
Scheelevägen 8
LUND, M 223 63
SE
LUND, M 223 63
SE
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||